Published in Eur Heart J on April 01, 2000
Left ventricular end-systolic volume as the major determinant of survival after recovery from myocardial infarction. Circulation (1987) 7.14
Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK Investigators. Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock. N Engl J Med (1999) 6.93
Sex, clinical presentation, and outcome in patients with acute coronary syndromes. Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes IIb Investigators. N Engl J Med (1999) 4.53
Cost effectiveness of early discharge after uncomplicated acute myocardial infarction. N Engl J Med (2000) 4.19
Effect of intravenous streptokinase on left ventricular function and early survival after acute myocardial infarction. N Engl J Med (1987) 4.08
ADP dissociation from actomyosin subfragment 1 is sufficiently slow to limit the unloaded shortening velocity in vertebrate muscle. Proc Natl Acad Sci U S A (1985) 4.01
Energetics and mechanism of actomyosin adenosine triphosphatase. Biochemistry (1976) 3.97
Guidelines for detection and management of dyslipidaemia. Scientific Committee of the National Heart Foundation of New Zealand. N Z Med J (1993) 3.18
Difference in countries' use of resources and clinical outcome for patients with cardiogenic shock after myocardial infarction: results from the GUSTO trial. Lancet (1997) 2.80
Prospective evaluation of eligibility for thrombolytic therapy in acute myocardial infarction. BMJ (1996) 2.62
Link between the angiographic substudy and mortality outcomes in a large randomized trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 2.53
Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Circulation (1993) 2.42
One-year survival following early revascularization for cardiogenic shock. JAMA (2001) 2.10
Stroke after thrombolysis. Mortality and functional outcomes in the GUSTO-I trial. Global Use of Strategies to Open Occluded Coronary Arteries. Circulation (1995) 2.08
Influence of diabetes mellitus on clinical outcome in the thrombolytic era of acute myocardial infarction. GUSTO-I Investigators. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 2.08
One-year results from the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation (1996) 2.03
Special instrumentation and techniques for kinetic studies of contractile systems. Methods Enzymol (1982) 2.02
Comparing health expenditure. N Z Med J (1996) 1.92
Acute myocardial infarction in the young--the role of smoking. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Eur Heart J (1995) 1.90
Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. Circulation (1996) 1.87
Kinetics of the interaction between actin, ADP, and cardiac myosin-S1. J Biol Chem (1984) 1.86
Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation (2001) 1.83
Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med (1997) 1.83
Waiting times and prioritization for coronary artery bypass surgery in New Zealand. Heart (1999) 1.81
Reduction of stroke events with pravastatin: the Prospective Pravastatin Pooling (PPP) Project. Circulation (2001) 1.78
Long-term survival and valve-related complications in young women with cardiac valve replacements. Circulation (1999) 1.77
Influence of diabetes mellitus on clinical outcomes across the spectrum of acute coronary syndromes. Findings from the GUSTO-IIb study. GUSTO IIb Investigators. Eur Heart J (2000) 1.73
Flow cytometric analysis of leukocytes in the human female reproductive tract: comparison of fallopian tube, uterus, cervix, and vagina. Am J Reprod Immunol (1997) 1.72
Light chain 2 profile and activity of human ventricular myosin during dilated cardiomyopathy. Identification of a causal agent for impaired myocardial function. Circulation (1992) 1.70
Cardiogenic shock complicating acute myocardial infarction--etiologies, management and outcome: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol (2000) 1.66
Reinfarction after thrombolytic therapy for acute myocardial infarction followed by conservative management: incidence and effect of smoking. J Am Coll Cardiol (1990) 1.64
Characterization of brain microtubule proteins prepared by selective removal of mitochondrial and synaptosomal components. J Biol Chem (1979) 1.59
Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease. Circulation (1999) 1.59
Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet (2000) 1.56
Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart (2008) 1.54
Platelet glycoprotein IIb/IIIa inhibition in acute coronary syndromes. Gradient of benefit related to the revascularization strategy. Eur Heart J (2002) 1.50
Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators. Circulation (1997) 1.47
Serum troponins T and I after elective cardioversion. Eur Heart J (2000) 1.45
Risk of intracranial haemorrhage with combined fibrinolytic and glycoprotein IIb/IIIa inhibitor therapy in acute myocardial infarction. Dichotomous response as a function of age in the GUSTO V trial. Eur Heart J (2003) 1.42
Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease. N Z Med J (1990) 1.39
New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J (2000) 1.39
A direct threat to research in public hospitals. N Z Med J (1995) 1.39
Cost of coronary heart disease in New Zealand. N Z Med J (1993) 1.38
Usefulness of the presenting electrocardiogram in predicting myocardial salvage with thrombolytic therapy in patients with a first acute myocardial infarction. Eur Heart J (2002) 1.38
Significance of diabetes mellitus in patients with acute myocardial infarction receiving thrombolytic therapy. Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. J Am Coll Cardiol (1993) 1.33
Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol (2000) 1.32
Unique CD8+ T cell-rich lymphoid aggregates in human uterine endometrium. J Leukoc Biol (1997) 1.31
Temperature and ligand dependence of conformation and helical order in myosin filaments. Biochemistry (2003) 1.27
Clinical and biochemical effects of dietary fish oil supplements in rheumatoid arthritis. J Rheumatol (1988) 1.24
End-systolic volume and long-term survival after coronary artery bypass graft surgery in patients with impaired left ventricular function. Circulation (1994) 1.20
Neutralizing antibodies to streptokinase four years after intravenous thrombolytic therapy. Am J Cardiol (1993) 1.20
Effects of mutations in the gamma-phosphate binding site of myosin on its motor function. J Biol Chem (1998) 1.19
Activated partial thromboplastin time and outcome after thrombolytic therapy for acute myocardial infarction: results from the GUSTO-I trial. Circulation (1996) 1.16
Diabetic retinopathy should not be a contraindication to thrombolytic therapy for acute myocardial infarction: review of ocular hemorrhage incidence and location in the GUSTO-I trial. Global Utilization of Streptokinase and t-PA for Occluded Coronary Arteries. J Am Coll Cardiol (1997) 1.15
Defective antigen-induced lymphocyte proliferation in the X-linked hyper-IgM syndrome. J Pediatr (1997) 1.14
Prophylactic lidocaine use in acute myocardial infarction: incidence and outcomes from two international trials. The GUSTO-I and GUSTO-IIb Investigators. Am Heart J (1999) 1.12
Observation of transient disorder during myosin subfragment-1 binding to actin by stopped-flow fluorescence and millisecond time resolution electron cryomicroscopy: evidence that the start of the crossbridge power stroke in muscle has variable geometry. Proc Natl Acad Sci U S A (1999) 1.11
Different mechanisms for Ca2+ dissociation from complexes of calmodulin with nitric oxide synthase or myosin light chain kinase. J Biol Chem (1996) 1.11
Risk factors for in-hospital nonhemorrhagic stroke in patients with acute myocardial infarction treated with thrombolysis: results from GUSTO-I. Circulation (1998) 1.08
Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin t-positive status: the paragon-B troponin T substudy. Circulation (2001) 1.07
Mechanism of oxyhaemoglobin breakdown on reaction with acetylphenylhydrazine. Biochem J (1978) 1.06
Aspirin does not improve early arterial patency after streptokinase treatment for acute myocardial infarction. Br Heart J (1993) 1.06
The results of surgical treatment of left ventricular aneurysms. An assessment of the risk factors affecting early and late mortality. J Thorac Cardiovasc Surg (1984) 1.06
Dithering over the treatment of diabetics with acute myocardial infarction. Eur Heart J (2000) 1.06
Postsystolic shortening of acutely ischemic canine myocardium predicts early and late recovery of function after coronary artery reperfusion. Circulation (1988) 1.06
Molecular cloning and characterization of grancalcin, a novel EF-hand calcium-binding protein abundant in neutrophils and monocytes. J Biol Chem (1992) 1.05
Transient detection of spin-labeled myosin subfragment 1 conformational states during ATP hydrolysis. Biochemistry (1993) 1.05
Effect of age on outcome with primary angioplasty versus thrombolysis. J Am Coll Cardiol (1999) 1.04
Superoxide dismutase as an inhibitor of reactions of semiquinone radicals. FEBS Lett (1978) 1.02
Treating menstruating women with thrombolytic therapy: insights from the global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries (GUSTO-I) trial. J Am Coll Cardiol (1995) 1.02
Uptake of chloroquine and hydroxychloroquine by human blood leucocytes in vitro: relation to cellular concentrations during antirheumatic therapy. Ann Rheum Dis (1987) 1.02
Support for the open-artery hypothesis in survivors of acute myocardial infarction: analysis of 11,228 patients treated with thrombolytic therapy. Am J Cardiol (1999) 1.01
Is our method of obtaining consent appropriate for randomised controlled trials in acute myocardial infarction? N Z Med J (1997) 1.01
Efficacy and safety of timolol for prevention of supraventricular tachyarrhythmias after coronary artery bypass surgery. Circulation (1984) 1.01
Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. Eur Heart J (2003) 1.00
Prediction of 30-day mortality among patients with thrombolysis-related intracranial hemorrhage. Circulation (1998) 0.98
The mucosal immune system in the human female reproductive tract: potential insights into the heterosexual transmission of HIV. AIDS Res Hum Retroviruses (1998) 0.98
Adenosine triphosphatase activity of bovine brain microtubule protein. J Biol Chem (1980) 0.98
Relation of increased arterial blood pressure to mortality and stroke in the context of contemporary thrombolytic therapy for acute myocardial infarction. A randomized trial. GUSTO-I Investigators. Ann Intern Med (1996) 0.96
Effects of streptokinase in patients presenting within 6 hours of prolonged chest pain with ST segment depression. Br Heart J (1995) 0.96
Flexibility within myosin heads revealed by negative stain and single-particle analysis. J Cell Biol (1997) 0.96
Gender and acute myocardial infarction: is there a different response to thrombolysis? J Am Coll Cardiol (1997) 0.96
Comparison of case fatality in smokers and non-smokers after acute cardiac event. BMJ (1997) 0.96
Comparative tolerability profiles of thrombolytic agents. A review. Drug Saf (1993) 0.95
Selection of thrombolytic therapy for individual patients: development of a clinical model. GUSTO-I Investigators. Am Heart J (1997) 0.94
Angiographic findings and clinical correlates in patients with cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK Trial Registry. SHould we emergently revascularize Occluded Coronaries for cardiogenic shocK? J Am Coll Cardiol (2000) 0.94
Survival 12 years after randomization to streptokinase: the influence of thrombolysis in myocardial infarction flow at three to four weeks. J Am Coll Cardiol (1999) 0.94